Exubera Reimbursement Plan May Focus On Outcomes Relative To Oral Agents
Executive Summary
Pfizer's strategy for securing reimbursement for Exubera could focus on the inhaled insulin's benefits on overall healthcare outcomes relative to oral diabetes therapies
You may also be interested in...
Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction
Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows
Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction
Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows
Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays
Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20